文献速递前列腺癌

生殖系BRCA2突变频率增加与多种族前列腺癌转移相关

Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2018-12-12

该研究对1240例前列腺癌患者(30%为非裔美国人)的血液DNA进行BRCA1/2靶向测序,发现已知致病性BRCA2突变在晚期和转移性前列腺癌中更常见(3.1% vs 器官局限性疾病0.7%),且非裔美国人携带未知意义变异(VUS)的频率更高(4.6% vs 1.6%)。携带BRCA2致病突变的局限早期患者远处转移风险增加。

要点

  • 致病性BRCA2突变在晚期/转移性前列腺癌中更常见(3.1% vs 0.7%)。
  • 非裔美国人BRCA1/2的VUS频率高于白种人(4.6% vs 1.6%)。
  • 携带BRCA2致病突变的局限早期患者远处转移风险增加。

核心结论

  • BRCA1/2的VUS在非裔美国前列腺癌患者中更频繁,但致病性突变患病率在不同种族间相似。
  • 携带BRCA2致病突变的患者更可能进展为转移。

研究设计与样本

  • 对1240例前列腺癌患者的存档血液DNA进行Ion AmpliSeq靶向测序BRCA1和BRCA2基因,包括30%非裔美国人。
  • 三个队列:局限早期(T2)前列腺癌(N=935);晚期前列腺癌(50%为T3-4)(N=189);转移性前列腺癌(N=116)。

主要发现

  • 具有已知致病性注释的BRCA2突变在晚期和转移性前列腺癌患者中显著更常见(3.1%),相比器官局限性疾病患者(0.7%)。
  • 非裔美国人携带BRCA1/2的VUS频率高于白种人(4.6% vs 1.6%)。
  • 局限早期前列腺癌男性中,致病性BRCA2突变显著增加远处转移风险。

临床怎么用

  • 对前列腺癌患者进行BRCA2致病突变检测可能有助于识别远处转移高风险者。
  • 解读非裔美国患者BRCA1/2结果时需注意VUS频率较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Germline mutations in BRCA2 have been linked to a higher risk of prostate cancer (PCa), and high frequency of BRCA1 and BRCA2 (BRCA1/2) gene alterations was recently reported in metastatic castration-resistant PCa specimens. Mutations in BRCA2 vary in racial and ethnic groups including African-American (AA) and Caucasian-American (CA) populations. METHODS: BRCA1 and BRCA2 genes were sequenced (Ion AmpliSeq targeted sequencing) in archived blood DNA specimens in 1240 PCa patients, including 30% AA patients, in three different cohorts: localized early stage (T2) PCa (N = 935); advanced PCa (50% T3-4) (N = 189); and metastatic PCa (N = 116). The sequences were analyzed for known and novel mutations in BRCA1/2. Statistical analyses were performed to determine associations of the mutations with clinico-pathological parameters. RESULTS: BRCA2 mutations with known pathogenic annotation were significantly more prevalent in men with advanced and metastatic PCa (3.1%) compared to patients with an organ-confined disease (0.7%). AA patients carried more frequently BRCA1/2 variants of unknown significance (VUS) when compared to Caucasian Americans (4.6 vs. 1.6%, respectively). Significantly, pathogenic BRCA2 mutations in men with localized early stage PCa increased the risk of distant metastasis. CONCLUSIONS: Germline variants of unknown significance in BRCA1/2 are more frequent in AA than CA PCa patients; however, the prevalence of pathogenic mutations were similar across the races. Patients carrying BRCA2 pathogenic mutations are more likely to progress to metastasis.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Petrovics G, Price DK, Lou H, et al. Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population. Prostate Cancer Prostatic Dis. 2018. PMID: 30542053. doi:10.1038/s41391-018-0114-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。